The above diagram shows the color scheme of the layout in the main result page. The parent entities and officers are those entities, including individual and legal persons, have significant controls over the company in focus. The offspring entities and appointments are those entities that the company in focus can influence on.

Clicking the links on parent entities or officers, and offspring entities or managed companies will put them in focus and show upstream or downstream connections. In general, ascendant entities can be found by moving toward upstream, and descendant entities are by toward downstream. In this way, progenitor entities such as grandparent companies (parents of parent), sibling companies (children of parent), partner companies (parents of child), and progeny entities such as grandchild companies (children of child) can be found easily.

Parent entities and officers
Active 3
  • 1
    Purkins, Lynn, Dr
    Vp, Clinical Operations born in April 1964
    Individual (4 offsprings)
    Officer
    2020-11-10 ~ dissolved
    OF - Director → CIF 0
  • 2
    Lam, Jennifer Phuong
    Individual (1 offspring)
    Officer
    2021-09-15 ~ dissolved
    OF - Secretary → CIF 0
  • 3
    Boardwalk, 18575 Jamboree Road, Suite 275-s, Irvine, Ca, United States
    Corporate (1 offspring)
    Person with significant control
    2021-04-08 ~ dissolved
    PE - Ownership of shares – 75% or more → CIF 0
Ceased 6
  • 1
    O'donnell, Niall Anthony, Dr.
    Chief Executive Officer born in July 1972
    Individual
    Officer
    2018-06-27 ~ 2020-11-11
    OF - Director → CIF 0
  • 2
    Tower, Deborah
    Individual
    Officer
    2018-01-08 ~ 2021-09-15
    OF - Secretary → CIF 0
  • 3
    Hall, Ashley Franchesca
    Chief Development Officer born in October 1971
    Individual
    Officer
    2021-10-20 ~ 2024-10-01
    OF - Director → CIF 0
  • 4
    Flesher, Gregory John
    President And Ceo born in June 1970
    Individual
    Officer
    2021-03-25 ~ 2024-10-04
    OF - Director → CIF 0
  • 5
    Johnson, Wendy
    Executive born in March 1952
    Individual
    Officer
    2018-01-08 ~ 2021-12-31
    OF - Director → CIF 0
  • 6
    Cruse, Michael Paul, Chief Operating Officer
    Chief Operating Officer born in March 1972
    Individual
    Officer
    2021-03-25 ~ 2024-10-04
    OF - Director → CIF 0
parent relation
Company in focus

RENEO PHARMA LTD

Standard Industrial Classification
72110 - Research And Experimental Development On Biotechnology
Brief company account
Average Number of Employees
222023-01-01 ~ 2023-12-31
212022-01-01 ~ 2022-12-31
Turnover/Revenue
33,301,776 GBP2023-01-01 ~ 2023-12-31
22,834,470 GBP2022-01-01 ~ 2022-12-31
Gross Profit/Loss
33,301,776 GBP2023-01-01 ~ 2023-12-31
22,834,470 GBP2022-01-01 ~ 2022-12-31
Administrative Expenses
-32,863,271 GBP2023-01-01 ~ 2023-12-31
-22,621,731 GBP2022-01-01 ~ 2022-12-31
Operating Profit/Loss
438,505 GBP2023-01-01 ~ 2023-12-31
212,739 GBP2022-01-01 ~ 2022-12-31
Other Interest Receivable/Similar Income (Finance Income)
7,462 GBP2023-01-01 ~ 2023-12-31
Profit/Loss on Ordinary Activities Before Tax
445,967 GBP2023-01-01 ~ 2023-12-31
212,739 GBP2022-01-01 ~ 2022-12-31
Profit/Loss
445,967 GBP2023-01-01 ~ 2023-12-31
406,748 GBP2022-01-01 ~ 2022-12-31
Property, Plant & Equipment
9,463 GBP2023-12-31
214,942 GBP2022-12-31
Debtors
Non-current
7,383 GBP2022-12-31
Current
11,608,204 GBP2023-12-31
4,745,499 GBP2022-12-31
Cash at bank and in hand
2,293,207 GBP2023-12-31
2,817,434 GBP2022-12-31
Current Assets
13,901,411 GBP2023-12-31
7,570,316 GBP2022-12-31
Creditors
Current, Amounts falling due within one year
-9,700,103 GBP2023-12-31
-4,574,841 GBP2022-12-31
Net Current Assets/Liabilities
4,201,308 GBP2023-12-31
2,995,475 GBP2022-12-31
Net Assets/Liabilities
4,210,771 GBP2023-12-31
3,210,417 GBP2022-12-31
Equity
Called up share capital
1 GBP2023-12-31
1 GBP2022-12-31
1 GBP2022-01-01
Retained earnings (accumulated losses)
4,210,770 GBP2023-12-31
3,210,416 GBP2022-12-31
2,236,915 GBP2022-01-01
Equity
4,210,771 GBP2023-12-31
3,210,417 GBP2022-12-31
2,236,916 GBP2022-01-01
Profit/Loss
Retained earnings (accumulated losses)
445,967 GBP2023-01-01 ~ 2023-12-31
406,748 GBP2022-01-01 ~ 2022-12-31
Audit Fees/Expenses
13,750 GBP2023-01-01 ~ 2023-12-31
9,000 GBP2022-01-01 ~ 2022-12-31
Wages/Salaries
3,100,132 GBP2023-01-01 ~ 2023-12-31
2,511,428 GBP2022-01-01 ~ 2022-12-31
Social Security Costs
304,820 GBP2023-01-01 ~ 2023-12-31
255,435 GBP2022-01-01 ~ 2022-12-31
Staff Costs/Employee Benefits Expense
3,473,597 GBP2023-01-01 ~ 2023-12-31
2,816,121 GBP2022-01-01 ~ 2022-12-31
Director Remuneration
307,881 GBP2023-01-01 ~ 2023-12-31
525,118 GBP2022-01-01 ~ 2022-12-31
Tax Expense/Credit at Applicable Tax Rate
104,802 GBP2023-01-01 ~ 2023-12-31
40,420 GBP2022-01-01 ~ 2022-12-31
Property, Plant & Equipment - Gross Cost
Office equipment
13,312 GBP2023-12-31
40,566 GBP2022-12-31
Property, Plant & Equipment - Gross Cost
13,312 GBP2023-12-31
238,248 GBP2022-12-31
Property, Plant & Equipment - Other Disposals
-375,226 GBP2023-01-01 ~ 2023-12-31
Property, Plant & Equipment - Accumulated Depreciation (Not Including Impairment)
Office equipment
23,306 GBP2022-12-31
Property, Plant & Equipment - Accumulated Depreciation (Not Including Impairment)
23,306 GBP2022-12-31
Property, Plant & Equipment - Increase From Depreciation Charge for Year
Office equipment, Owned/Freehold
12,060 GBP2023-01-01 ~ 2023-12-31
Owned/Freehold
76,174 GBP2023-01-01 ~ 2023-12-31
Property, Plant & Equipment - Other Disposals/Decrease in Depreciation & Impairment
-95,631 GBP2023-01-01 ~ 2023-12-31
Property, Plant & Equipment - Accumulated Depreciation & Impairment
Office equipment
3,849 GBP2023-12-31
Property, Plant & Equipment - Accumulated Depreciation & Impairment
3,849 GBP2023-12-31
Property, Plant & Equipment
Office equipment
9,463 GBP2023-12-31
17,260 GBP2022-12-31
Other Debtors
Non-current
7,383 GBP2022-12-31
Amounts Owed by Group Undertakings
Current
8,997,680 GBP2023-12-31
2,087,901 GBP2022-12-31
Other Debtors
Current
1,906,015 GBP2023-12-31
1,286,689 GBP2022-12-31
Prepayments/Accrued Income
Current
704,509 GBP2023-12-31
1,370,909 GBP2022-12-31
Trade Creditors/Trade Payables
Current
4,936,009 GBP2023-12-31
1,192,248 GBP2022-12-31
Taxation/Social Security Payable
Current
667,215 GBP2023-12-31
269,872 GBP2022-12-31
Other Creditors
Current
165,985 GBP2023-12-31
73,190 GBP2022-12-31
Accrued Liabilities/Deferred Income
Current
3,930,894 GBP2023-12-31
3,039,531 GBP2022-12-31
Creditors
Current
9,700,103 GBP2023-12-31
4,574,841 GBP2022-12-31
Number of Shares Issued (Fully Paid)
Class 1 ordinary share
100 shares2023-12-31
100 shares2022-12-31
Par Value of Share
Class 1 ordinary share
0.012023-01-01 ~ 2023-12-31
Future Minimum Lease Payments Under Non-cancellable Operating Leases
Amounts falling due within one year
47,667 GBP2022-12-31
Between one and five year
212,333 GBP2022-12-31
Future Minimum Lease Payments Under Non-cancellable Operating Leases
260,000 GBP2022-12-31
  • RENEO PHARMA LTD
    Info
    Registered number 11136706
    Office 20, Second Floor Innovation House, Innovation Way, Discovery Park, Sandwich, Kent CT13 9FF
    Private Limited Company incorporated on 2018-01-08 and dissolved on 2024-12-31 (6 years 11 months). The company status is Dissolved.
    The last date of confirmation statement was made at 2024-01-03
    CIF 0
child relation
Offspring entities and appointments
Active 0
  • Not found in our database.

qrcode

Privacy notice

Terms and conditions

© 2022-2025 Polylogarithmic Technology Ltd. All rights reserved.
Contains public sector information retrieved at 24 April 2025 and licensed under the Open Government Licence v3.0.